Johnson & Johnson Rules Out Big Acquisitions, Reiterates Focus On Small Deals: Analyst

Core Insights - Johnson & Johnson reported a third-quarter 2025 adjusted earnings of $2.80 per share, a 15.7% increase year over year, surpassing the consensus estimate of $2.75 [1] - The company plans to separate its Orthopedics business, which will operate as DePuy Synthes, aiming for completion within 18 to 24 months [2] - Bank of America noted that the revenue beat was primarily driven by Stelara, with a slight increase in fiscal 2025 revenue guidance [3] - Analysts believe the separation will enhance focus and competitiveness for DePuy Synthes [3] - Johnson & Johnson is focusing on smaller acquisitions rather than large ones, stating that major M&A is not necessary to meet long-term growth targets [4] - The stock price of Johnson & Johnson is currently down 0.70% at $189.51 [4]